Urologist to study herbal remedies for prostate and urinary diseases

December 08, 2003

(Kingston, ON) - For the first time in North America, non-traditional methods of treating painful prostate and bladder diseases that will affect more than 50 % of the adult population are being scientifically studied by a Queen's University-based research team working out of Kingston General Hospital (KGH).

Dr. J. Curtis Nickel, professor of Urology at Queen's and urologist at KGH, has been awarded an unprecedented four research grants from the U.S. National Institutes of Health (NIH), totaling almost $8 million. He and his Kingston Genito-urinary Research Group will examine alternative, complementary and novel therapies for prostate and bladder disease, in both laboratory research and clinical trials that will involve more than 3,000 men and women throughout southern Ontario.

"For these diseases, traditional medicine has offered all it can," says Dr. Nickel. "Alternative herbal therapies - which people have been using for more than 4,000 years - complementary therapies, and radically novel treatments must be evaluated by traditional clinical scientists, to determine their true effectiveness and safety."

The NIH, which coordinates all government health care research in the United States, has been directed by the U.S. Congress to look at herbal therapies that now make up a billion-dollar industry in North America. "It's exciting to embark on such a wide-ranging project with potential applications in so many areas," says Dr. Curtis. "There are probably more herbal than prescribed pharmaceutical treatments sold in Canada today - but, without clinical evaluation, we don't know how safe they are, or whether they really work!"

The Queen's/KGH group has taken a leading role in designing, implementing and completing local, national and international multi-centre studies in benign diseases of the urinary tract. These studies have evaluated the traditional medical therapies currently used for these conditions.

The new programs will build on findings from the group's earlier, $2-million pilot project, also funded by NIH, which was completed earlier this year.

The new studies involve laboratory research and clinical trials in the following areas: "One of the reasons we received these grants is that we believe the two areas of disease - one mainly in women and the other in men - are related," says Dr. Nickel. "The treatments we're looking at, for prostate disease in men and bladder disease in women, will be very similar."

Because the population base in southeastern Ontario could not support such large clinical trials, Dr. Nickel is collaborating with two Toronto researchers who will recruit volunteers from a network of primary care urologists in private practice. The group is now conducting "stability" studies on its sources of herbal remedies - a process that is valuable in itself, since it has never been done before. Trials are scheduled to begin this spring in collaboration with a number of U.S. universities, including Harvard, Tufts, UCLA, and Pennsylvania.

The Kingston Genito-urinary Research Group has been supported by KGH and Queen's since its inception more than 10 years ago. Other team members in the recently funded group are Drs. Alvaro Morales and Robert Siemens (Urology), Dr Dean Tripp (Psychology) a research fellow, a research coordinator, a research associate, an acupuncturist, and four research nurses.
-end-
Additional Contact:
Lorinda Peterson, Queen's News & Media Services, 613.533.3234

Queen's University

Related Clinical Trials Articles from Brightsurf:

Nearly 1 in 5 cancer patients less likely to enroll in clinical trials during pandemic
A significant portion of cancer patients may be less likely to enroll in a clinical trial due to the ongoing coronavirus pandemic.

COVID-19 clinical trials lack diversity
Despite disproportionately higher rates of COVID-19 infection, hospitalization and death among people of color, minority groups are significantly underrepresented in COVID-19 clinical trials.

Why we should trust registered clinical trials
In a time when we have to rely on clinical trials for COVID-19 drugs and vaccines, a new study brings good news about the credibility of registered clinical trials.

Inclusion of children in clinical trials of treatments for COVID-19
This Viewpoint discusses the exclusion of children from coronavirus disease 2019 (COVID-19) clinical trials and why that could harm treatment options for children.

Review evaluates how AI could boost the success of clinical trials
In a review publishing July 17, 2019 in the journal Trends in Pharmacological Sciences, researchers examined how artificial intelligence (AI) could affect drug development in the coming decade.

Kidney patients are neglected in clinical trials
The exclusion of patients with kidney diseases from clinical trials remains an unsolved problem that hinders optimal care of these patients.

Clinical trials beginning for possible preeclampsia treatment
For over 20 years, a team of researchers at Lund University has worked on developing a drug against preeclampsia -- a serious disorder which annually affects around 9 million pregnant women worldwide and is one of the main causes of death in both mothers and unborn babies.

Underenrollment in clinical trials: Patients not the problem
The authors of the study published this month in the Journal of Clinical Oncology investigated why many cancer clinical trials fail to enroll enough patients.

When designing clinical trials for huntington's disease, first ask the experts
Progress in understanding the genetic mutation responsible for Huntington's disease (HD) and at least some molecular underpinnings of the disease has resulted in a new era of clinical testing of potential treatments.

New ALS therapy in clinical trials
New research led by Washington University School of Medicine in St.

Read More: Clinical Trials News and Clinical Trials Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.